Eli Lilly (LLY) said Tuesday that it has launched 7.5 milligram and 10 milligram single-dose vials of Zepbound or Tirzepatide, priced at $499 per month through its self-pay Journey program.

The company also said it has lowered the prices of its 2.5 milligram and 5 milligram vials to $349 and $499 per month, respectively.

These new options are only available through "LillyDirect," Eli Lilly said, a system for direct pricing that removes third-party supply chain involvement.

Zepbound is also available in prefilled pens, with weekly maintenance doses of 5 milligrams, 10 milligrams, or 15 milligrams, the company said.

The company's shares were up 1.8% in recent Tuesday premarket activity.

Price: 896.51, Change: +15.11, Percent Change: +1.7